AU2003267751A1 - Use of epothilone derivatives for the treatment of hyperparathyroidism - Google Patents

Use of epothilone derivatives for the treatment of hyperparathyroidism

Info

Publication number
AU2003267751A1
AU2003267751A1 AU2003267751A AU2003267751A AU2003267751A1 AU 2003267751 A1 AU2003267751 A1 AU 2003267751A1 AU 2003267751 A AU2003267751 A AU 2003267751A AU 2003267751 A AU2003267751 A AU 2003267751A AU 2003267751 A1 AU2003267751 A1 AU 2003267751A1
Authority
AU
Australia
Prior art keywords
hyperparathyroidism
treatment
epothilone derivatives
animal
epothilone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267751A
Other languages
English (en)
Inventor
Eugene A. Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of AU2003267751A1 publication Critical patent/AU2003267751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2003267751A 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism Abandoned AU2003267751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
US60/418,592 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (1)

Publication Number Publication Date
AU2003267751A1 true AU2003267751A1 (en) 2004-05-04

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267751A Abandoned AU2003267751A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Country Status (15)

Country Link
US (2) US20060142354A1 (enExample)
EP (1) EP1553938B1 (enExample)
JP (1) JP4672368B2 (enExample)
CN (1) CN1297269C (enExample)
AT (1) ATE350034T1 (enExample)
AU (1) AU2003267751A1 (enExample)
BR (1) BR0315293A (enExample)
CA (1) CA2501717C (enExample)
CY (1) CY1106385T1 (enExample)
DE (1) DE60310975T2 (enExample)
DK (1) DK1553938T3 (enExample)
ES (1) ES2279139T3 (enExample)
PT (1) PT1553938E (enExample)
SI (1) SI1553938T1 (enExample)
WO (1) WO2004035050A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1155689E (pt) * 1993-07-19 2007-01-31 Angiotech Pharm Inc Composições anti-angiogenicas e metodos de utilização
WO1998022461A1 (de) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
HK1080768A1 (en) 2006-05-04
JP2006504751A (ja) 2006-02-09
DE60310975D1 (de) 2007-02-15
DE60310975T2 (de) 2007-07-12
CN1703217A (zh) 2005-11-30
ES2279139T3 (es) 2007-08-16
CY1106385T1 (el) 2011-10-12
US20110152329A1 (en) 2011-06-23
EP1553938A1 (en) 2005-07-20
CA2501717A1 (en) 2004-04-29
CN1297269C (zh) 2007-01-31
ATE350034T1 (de) 2007-01-15
CA2501717C (en) 2012-09-18
BR0315293A (pt) 2005-08-30
PT1553938E (pt) 2007-03-30
DK1553938T3 (da) 2007-03-26
US20060142354A1 (en) 2006-06-29
SI1553938T1 (sl) 2007-06-30
WO2004035050A1 (en) 2004-04-29
JP4672368B2 (ja) 2011-04-20
EP1553938B1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
ATE440603T1 (de) 8-hydroxychinolinderivate
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
MY138352A (en) Benzothiazole derivatives
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
WO2003080582A3 (de) Fredericamycin-derivate
TW200420549A (en) Thiazole derivatives
GB0225475D0 (en) Therapeutic agents
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
WO2006011631A3 (en) Thiazole derivatives having vap-1 inhibitory activity
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
IN2005KO00312A (enExample)
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
WO2004044174A3 (en) Topoisomerase-targeting agents
AU2003267751A1 (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
IL156140A0 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
HK1080369A1 (zh) 用於治疗多发性骨髓瘤的埃博霉素衍生物
AU2003216965A1 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase